Scholarlink

Purpose <p>The main objective of this study was to systematically evaluate the effectiveness of pharmacogenomics-guided treatment (PGxT) and treatment-as-usual (TAU) in schizophrenia management through two key indicators: medication adherence and antipsychotic switching rate.</p> Methods <p>The study cohort comprised individuals with schizophrenia who were hospitalized between April 2022 and March 2024. The cohort was stratified into two groups: the PGxT and TAU. To address potential confounding between the groups, propensity score matching (PSM) was applied. The primary outcome measures were the proportions of patients with good medication adherence (≥ 80%) at three and six months after discharge and the antipsychotic switching rate.</p> Results <p>Among the 420 patients in the PGxT and TAU groups obtained through propensity score matching, the proportions of patients with good medication adherence (≥ 80%) was 49.76% at three months and 33.10% at six months, with a significant difference between the follow-up periods (<i>P</i> &lt; 0.001). During the three-month observation period, the proportion of patients demonstrating good adherence were significantly different (55.24% in PGxT group vs. 44.29% in TAU group; <i>P</i> = 0.032). The difference was also significant after six months (44.76% in PGxT group vs. 21.43% in TAU group; <i>P</i> &lt; 0.001). Furthermore, the proportion of antipsychotic switching rate was lower in the PGxT group (25.71%) than in the TAU group (41.90%) (<i>P</i> &lt; 0.001).</p> Conclusion <p>This study observed an association between PGxT and higher adherence as well as lower medication switching rate in patients with schizophrenia, which suggests potential clinical utility of PGx testing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate

  • 期刊论文

  • 发表日期：

    2025年6月6日

查看全文
  • Jiaqi Wang,
  • Yuhang Yan,
  • Liguang Duan,
  • Binliang Tong,
  • Xiaochuan Zhao,
  • Shi Su,
  • Mengqiang Zhao,
  • Chaoli Chen,
  • Yang Lun,
  • Yueyao Luan,
  • Qixuan Sun,
  • Yuanyuan Zhao,
  • Jing Yu,
  • Xiaoying Geng,
  • Jincheng Wang,
  • Chunhua Zhou

摘要

Purpose

The main objective of this study was to systematically evaluate the effectiveness of pharmacogenomics-guided treatment (PGxT) and treatment-as-usual (TAU) in schizophrenia management through two key indicators: medication adherence and antipsychotic switching rate.

Methods

The study cohort comprised individuals with schizophrenia who were hospitalized between April 2022 and March 2024. The cohort was stratified into two groups: the PGxT and TAU. To address potential confounding between the groups, propensity score matching (PSM) was applied. The primary outcome measures were the proportions of patients with good medication adherence (≥ 80%) at three and six months after discharge and the antipsychotic switching rate.

Results

Among the 420 patients in the PGxT and TAU groups obtained through propensity score matching, the proportions of patients with good medication adherence (≥ 80%) was 49.76% at three months and 33.10% at six months, with a significant difference between the follow-up periods (P < 0.001). During the three-month observation period, the proportion of patients demonstrating good adherence were significantly different (55.24% in PGxT group vs. 44.29% in TAU group; P = 0.032). The difference was also significant after six months (44.76% in PGxT group vs. 21.43% in TAU group; P < 0.001). Furthermore, the proportion of antipsychotic switching rate was lower in the PGxT group (25.71%) than in the TAU group (41.90%) (P < 0.001).

Conclusion

This study observed an association between PGxT and higher adherence as well as lower medication switching rate in patients with schizophrenia, which suggests potential clinical utility of PGx testing.